The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Samsung Bioepis files U.S. approval application for Keytruda biosimilar SB27

Oct 30, 2026 08:11 (7h ago)

Verifying

Samsung Bioepis filed U.S. approval application for SB27, a Keytruda biosimilar candidate.
18 conditions, including melanoma and lung cancer, are covered by the application.
Samsung Bioepis began global SB27 trials in 2024 and filed in South Korea in August.